{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:20:27Z","timestamp":1780392027126,"version":"3.54.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-026-03401-x","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T22:38:12Z","timestamp":1773700692000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Polymer-Surfactant Stabilized Amorphous Nanosuspension of Pazopanib: Box-Behnken Optimization and In-vivo Evaluation"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9322-732X","authenticated-orcid":false,"given":"Vanshul","family":"Saini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5371-2151","authenticated-orcid":false,"given":"Ashish","family":"Hankare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2955-6454","authenticated-orcid":false,"given":"Prakash","family":"Amate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7829-940X","authenticated-orcid":false,"given":"Mehak","family":"Juneja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3733-9444","authenticated-orcid":false,"given":"Mahesh","family":"Kashyap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0259-9956","authenticated-orcid":false,"given":"Abhay T.","family":"Sangamwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"issue":"9829","key":"3401_CR1","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","volume":"379","author":"WTA Van Der Graaf","year":"2012","unstructured":"Van Der Graaf WTA, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879\u201386.","journal-title":"Lancet"},{"issue":"6","key":"3401_CR2","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1093\/jjco\/hyy053","volume":"48","author":"S Miyamoto","year":"2018","unstructured":"Miyamoto S, Kakutani S, Sato Y, Hanashi A, Kinoshita Y, Ishikawa A. Drug review: pazopanib. Jpn J Clin Oncol. 2018;48(6):503\u201313.","journal-title":"Jpn J Clin Oncol"},{"issue":"5","key":"3401_CR3","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3109\/00498254.2012.734642","volume":"43","author":"Y Deng","year":"2013","unstructured":"Deng Y, Sychterz C, Suttle AB, Dar MM, Bershas D, Negash K, et al. Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica. 2013;43(5):443\u201353.","journal-title":"Xenobiotica"},{"key":"3401_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2024.100995","volume":"55","author":"HJ Muhammad","year":"2024","unstructured":"Muhammad HJ, Shimada T, Fujita A, Sai Y. Sodium citrate buffer improves pazopanib solubility and absorption in gastric acid-suppressed rat model. Drug Metab Pharmacokinet. 2024;55:100995. https:\/\/doi.org\/10.1016\/j.dmpk.2024.100995.","journal-title":"Drug Metab Pharmacokinet"},{"key":"3401_CR5","unstructured":"FDA_PIL_Votrient. Votrient. Pazopanib. Highlights of Prescribing Information. Novartis Pharmaceuticals Corporation. Available: 2024; Available from: https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/votrient.pdf. Accessed 12 Jan 2026"},{"issue":"10","key":"3401_CR6","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1038\/bjc.2014.503","volume":"111","author":"AB Suttle","year":"2014","unstructured":"Suttle AB, Ball HA, Molimard M, Hutson TE, Carpenter C, Rajagopalan D, et al. Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Br J Cancer. 2014;111(10):1909\u201316.","journal-title":"Br J Cancer"},{"issue":"9","key":"3401_CR7","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s40262-017-0510-z","volume":"56","author":"RB Verheijen","year":"2017","unstructured":"Verheijen RB, Beijnen JH, Schellens JHM, Huitema ADR, Steeghs N. Clinical pharmacokinetics and pharmacodynamics of pazopanib: towards optimized dosing. Clin Pharmacokinet. 2017;56(9):987\u201397.","journal-title":"Clin Pharmacokinet"},{"key":"3401_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.122287","volume":"628","author":"SJ Nadaf","year":"2022","unstructured":"Nadaf SJ, Killedar SG, Kumbar VM, Bhagwat DA, Gurav SS. Pazopanib-laden lipid based nanovesicular delivery with augmented oral bioavailability and therapeutic efficacy against non-small cell lung cancer. Int J Pharm. 2022;628:122287. https:\/\/doi.org\/10.1016\/j.ijpharm.2022.122287.","journal-title":"Int J Pharm"},{"key":"3401_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2025.115034","volume":"256","author":"K Rode","year":"2025","unstructured":"Rode K, Maji I, Dhuri A, Manoharan B, Kanp T, Athavan E, et al. Enhancing oral bioavailability of pazopanib via co-amorphous system: formulation, characterization, pharmacokinetics and toxicity evaluation. Colloids Surf B Biointerfaces. 2025;256:115034. https:\/\/doi.org\/10.1016\/j.colsurfb.2025.115034.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"3401_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16060764","author":"A Gupta","year":"2024","unstructured":"Gupta A, Dahima R, Panda SK, Gupta A, Singh GD, Wani TA, et al. QbD-based development and evaluation of pazopanib hydrochloride extrudates prepared by hot-melt extrusion technique: in vitro and in vivo evaluation. Pharmaceutics. 2024. https:\/\/doi.org\/10.3390\/pharmaceutics16060764.","journal-title":"Pharmaceutics"},{"key":"3401_CR11","doi-asserted-by":"publisher","unstructured":"Sachdeva V, Mehra A, Singh G, Kumar A, Kumar P, Singh G, et al. Self-microemulsifying drug delivery system-based gastroretentive in situ raft of pazopanib with enhanced solubility and bioavailability. Arch Pharm (Weinheim) [Internet]. 2025 Jan 1 [cited 2025 Sep 4];358(1):e2400179. Available from: \/doi\/pdf\/https:\/\/doi.org\/10.1002\/ardp.202400179","DOI":"10.1002\/ardp.202400179"},{"issue":"4","key":"3401_CR12","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2174\/157341309789378177","volume":"5","author":"X Pu","year":"2012","unstructured":"Pu X, Sun J, Li M, He Z. Formulation of nanosuspensions as a new approach for the delivery of poorly soluble drugs. Curr Nanosci. 2012;5(4):417\u201327.","journal-title":"Curr Nanosci"},{"key":"3401_CR13","doi-asserted-by":"crossref","unstructured":"Tsiaxerli A, Vardaka E, Moutroupidis C, Taylor KMG, Kachrimanis K, Malamatari M. solid oral dosage forms. 2024;32(4).","DOI":"10.38212\/2224-6614.3525"},{"key":"3401_CR14","doi-asserted-by":"crossref","unstructured":"Jacob S, Kather FS, Boddu SHS, Attimarad M. Nanosuspension Innovations\u202f: Expanding Horizons in Drug Delivery Techniques. 2025;1\u201361.","DOI":"10.3390\/pharmaceutics17010136"},{"key":"3401_CR15","doi-asserted-by":"crossref","unstructured":"Jacob S, Nair AB, Shah J. Emerging role of nanosuspensions in drug delivery systems. 2020;1\u201316.","DOI":"10.1186\/s40824-020-0184-8"},{"issue":"4","key":"3401_CR16","doi-asserted-by":"publisher","first-page":"574","DOI":"10.26599\/NBE.2024.9290092","volume":"16","author":"NP Mane","year":"2024","unstructured":"Mane NP, Rane BR, Jain AS. Nano Biomed Eng Advances in Nanosuspension Technology\u202f: Current Trends and Future Horizons. 2024;16(4):574\u201387.","journal-title":"Nano Biomed Eng Advances in Nanosuspension Technology : Current Trends and Future Horizons"},{"key":"3401_CR17","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3390\/cryst11121440","volume":"11","author":"Y Wang","year":"2021","unstructured":"Wang Y, Wang Y, Cheng J, Chen H, Xu J, Liu Z, Shi Q, Zhang C. Recent Advances in the Application of Characterization Techniques for Studying Physical Stability of Amorphous Pharmaceutical Solids. Crystals. 2021;11:1440. https:\/\/doi.org\/10.3390\/cryst11121440.","journal-title":"Crystals"},{"issue":"1","key":"3401_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.xphs.2024.08.029","volume":"114","author":"K Ueda","year":"2025","unstructured":"Ueda K, Moseson DE, Taylor LS. Amorphous solubility advantage\u202f: theoretical considerations , experimental methods , and contemporary relevance. J Pharm Sci. 2025;114(1):18\u201339. https:\/\/doi.org\/10.1016\/j.xphs.2024.08.029.","journal-title":"J Pharm Sci"},{"key":"3401_CR19","first-page":"16","volume":"34","author":"G Karthick","year":"2022","unstructured":"Karthick G, Akiladevi D, Ahamed MI. A Comprehensive Review of a New Nanosuspension for Improving the Oral Bioavailability of Poorly Soluble Drugs. 2022;34:16\u201321.","journal-title":"A Comprehensive Review of a New Nanosuspension for Improving the Oral Bioavailability of Poorly Soluble Drugs"},{"key":"3401_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2025.114809","volume":"214","author":"R Singh","year":"2025","unstructured":"Singh R, Juneja M, Saini V, Malviya R, Kshirsagar R, Kashyap M, et al. Synergistic approach of salt formation and polymer-mediated stabilization to enhance the biopharmaceutical performance of Mebendazole. Eur J Pharm Biopharm. 2025;214:114809. https:\/\/doi.org\/10.1016\/j.ejpb.2025.114809.","journal-title":"Eur J Pharm Biopharm"},{"key":"3401_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics10030160","author":"A Girdhar","year":"2018","unstructured":"Girdhar A, Thakur PS, Sheokand S, Bansal AK. Permeability behavior of nanocrystalline solid dispersion of dipyridamole generated using NanoCrySP technology. Pharmaceutics. 2018. https:\/\/doi.org\/10.3390\/pharmaceutics10030160.","journal-title":"Pharmaceutics"},{"issue":"1","key":"3401_CR22","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1080\/10717544.2019.1704940","volume":"27","author":"A Schittny","year":"2020","unstructured":"Schittny A, Huwyler J, Puchkov M. Mechanisms of increased bioavailability through amorphous solid dispersions: a review. Drug Deliv. 2020;27(1):110\u201327. https:\/\/doi.org\/10.1080\/10717544.2019.1704940.","journal-title":"Drug Deliv"},{"key":"3401_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics10030092","author":"C Qin","year":"2018","unstructured":"Qin C, Xin X, Pei X, Yin L, He W. Amorphous nanosuspensions aggregated from paclitaxel-hemoglobulin complexes with enhanced cytotoxicity. Pharmaceutics. 2018. https:\/\/doi.org\/10.3390\/pharmaceutics10030092.","journal-title":"Pharmaceutics"},{"key":"3401_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejpb.2020.07.001","volume":"154","author":"H Van Ngo","year":"2020","unstructured":"Van Ngo H, Park C, Tran TTD, Nguyen VH, Lee BJ. Mechanistic understanding of salt-induced drug encapsulation in nanosuspension via acid-base neutralization as a nanonization platform technology to enhance dissolution rate of pH-dependent poorly water-soluble drugs. Eur J Pharm Biopharm. 2020;154:8\u201317.","journal-title":"Eur J Pharm Biopharm"},{"issue":"3","key":"3401_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12247-025-09991-6","volume":"20","author":"CD Nayak","year":"2025","unstructured":"Nayak CD, Sudheer P, Khan AB, Muthanna B. Development and evaluation of carvedilol nanosuspension by acid base neutralization method. J Pharm Innov. 2025;20(3):1\u201316.","journal-title":"J Pharm Innov"},{"key":"3401_CR26","doi-asserted-by":"crossref","unstructured":"Ambhore NP, Dandagi PM. Formulation and comparative evaluation of HPMC and water soluble chitosan-based sparfloxacin nanosuspension for ophthalmic delivery. 2016;48\u201356.","DOI":"10.1007\/s13346-015-0262-y"},{"issue":"11","key":"3401_CR27","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1021\/acs.oprd.3c00204","volume":"27","author":"P Ghosh","year":"2023","unstructured":"Ghosh P, Rasmuson A, Hudson SP. Impact of additives on drug particles during liquid antisolvent crystallization and subsequent freeze-drying. Org Process Res Dev. 2023;27(11):2020\u201334.","journal-title":"Org Process Res Dev"},{"issue":"2","key":"3401_CR28","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ejpb.2011.04.010","volume":"79","author":"SM Fischer","year":"2011","unstructured":"Fischer SM, Brandl M, Fricker G. Effect of the non-ionic surfactant Poloxamer 188 on passive permeability of poorly soluble drugs across Caco-2 cell monolayers. Eur J Pharm Biopharm. 2011;79(2):416\u201322. https:\/\/doi.org\/10.1016\/j.ejpb.2011.04.010.","journal-title":"Eur J Pharm Biopharm"},{"issue":"2","key":"3401_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/s12249-025-03040-8","volume":"26","author":"P Sayyad","year":"2025","unstructured":"Sayyad P, Jha S, Sharma R, Yadav V, Jain S. Unveiling the potential of nanosuspension formulation strategy for improved oral bioavailability of Gefitinib. AAPS PharmSciTech. 2025;26(2):1\u201316. https:\/\/doi.org\/10.1208\/s12249-025-03040-8.","journal-title":"AAPS PharmSciTech"},{"key":"3401_CR30","doi-asserted-by":"crossref","unstructured":"Gajera B, Shah H, Parekh B, Rathod V, Tilala M, Dave RH. Design of Experiments-Driven Optimization of Spray Drying for Amorphous Clotrimazole Nanosuspension. 2024;1\u201311.","DOI":"10.1208\/s12249-024-02871-1"},{"issue":"7","key":"3401_CR31","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1080\/03639045.2017.1304955","volume":"43","author":"K Nagaraj","year":"2017","unstructured":"Nagaraj K, Narendar D, Kishan V. Development of olmesartan medoxomil optimized nanosuspension using the Box\u2013Behnken design to improve oral bioavailability. Drug Dev Ind Pharm. 2017;43(7):1186\u201396.","journal-title":"Drug Dev Ind Pharm"},{"issue":"8","key":"3401_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics15082037","volume":"15","author":"O Boscolo","year":"2023","unstructured":"Boscolo O, Flor S, Salvo L, Dobrecky C, H\u00f6cht C, Tripodi V, et al. Formulation and characterization of Ursodeoxycholic Acid Nanosuspension based on bottom-up technology and Box\u2013Behnken design optimization. Pharmaceutics. 2023;15(8):1\u201318.","journal-title":"Pharmaceutics"},{"issue":"15","key":"3401_CR33","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1039\/D2CE00050D","volume":"24","author":"EM Peters","year":"2022","unstructured":"Peters EM, Sv\u00e4rd M, Forsberg K. Impact of process parameters on product size and morphology in hydrometallurgical antisolvent crystallization. CrystEngComm. 2022;24(15):2851\u201366.","journal-title":"CrystEngComm"},{"issue":"10","key":"3401_CR34","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1007\/s13346-023-01334-7","volume":"13","author":"M Chougule","year":"2023","unstructured":"Chougule M, Sirvi A, Saini V, Kashyap M, Sangamwar AT. Enhanced biopharmaceutical performance of brick dust molecule nilotinib via stabilized amorphous nanosuspension using a facile acid\u2013base neutralization approach. Drug Deliv Transl Res. 2023;13(10):2503\u201319. https:\/\/doi.org\/10.1007\/s13346-023-01334-7.","journal-title":"Drug Deliv Transl Res"},{"issue":"6","key":"3401_CR35","doi-asserted-by":"publisher","first-page":"57","DOI":"10.22159\/ijap.2024v16i6.51843","volume":"16","author":"TI Hanum","year":"2024","unstructured":"Hanum TI, Prasetyo BE, Fadilla W. Formulation and in vitro tests of ketoprofen nanosuspension using the milling method with polymer variations. Int J Appl Pharm. 2024;16(6):57\u201363.","journal-title":"Int J Appl Pharm"},{"key":"3401_CR36","doi-asserted-by":"crossref","unstructured":"Roldan TL, Li S, Guillon C, Heindel ND, Laskin JD, Lee IH, et al. Optimizing Nanosuspension Drug Release and Wound Healing Using a Design of Experiments Approach\u202f: Improving the Drug Delivery Potential of NDH-4338 for Treating Chemical Burns. 2024;1\u201319.","DOI":"10.3390\/pharmaceutics16040471"},{"issue":"2","key":"3401_CR37","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s13346-024-01630-w","volume":"15","author":"M Juneja","year":"2025","unstructured":"Juneja M, Mehtre K, Saini V, Singh R, Amate P, Kashyap M, et al. Synergistic effect of polymers in stabilizing amorphous pretomanid through high drug loaded amorphous solid dispersion. Drug Deliv Transl Res. 2025;15(2):717\u201331.","journal-title":"Drug Deliv Transl Res"},{"key":"3401_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2024.105393","volume":"92","author":"T Wang","year":"2024","unstructured":"Wang T, Staufenbiel S. Preparation and characterization of stabilizer-free oily nanosuspensions. J Drug Deliv Sci Technol. 2024;92:105393. https:\/\/doi.org\/10.1016\/j.jddst.2024.105393.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3401_CR39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ejpb.2020.04.017","volume":"152","author":"J Plum","year":"2020","unstructured":"Plum J, Bavnh\u00f8j CG, Eliasen JN, Rades T, M\u00fcllertz A. Comparison of induction methods for supersaturation: amorphous dissolution versus solvent shift. Eur J Pharm Biopharm. 2020;152:35\u201343. https:\/\/doi.org\/10.1016\/j.ejpb.2020.04.017.","journal-title":"Eur J Pharm Biopharm"},{"key":"3401_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.102046","volume":"60","author":"M Kurakula","year":"2020","unstructured":"Kurakula M, Rao GSNK. Pharmaceutical assessment of polyvinylpyrrolidone (PVP): as excipient from conventional to controlled delivery systems with a spotlight on COVID-19 inhibition. J Drug Deliv Sci Technol. 2020;60:102046. https:\/\/doi.org\/10.1016\/j.jddst.2020.102046.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3401_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics8020017","author":"M Li","year":"2016","unstructured":"Li M, Azad M, Dav\u00e9 R, Bilgili E. Nanomilling of drugs for bioavailability enhancement: a holistic formulation-process perspective. Pharmaceutics. 2016. https:\/\/doi.org\/10.3390\/pharmaceutics8020017.","journal-title":"Pharmaceutics"},{"key":"3401_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2023.104519","author":"MS Attia","year":"2023","unstructured":"Attia MS, Elshahat A, Hamdy A, Fathi AM, Emad-Eldin M, Ghazy FES, et al. Soluplus\u00ae as a solubilizing excipient for poorly water-soluble drugs: recent advances in formulation strategies and pharmaceutical product features. J Drug Deliv Sci Technol. 2023. https:\/\/doi.org\/10.1016\/j.jddst.2023.104519.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3401_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232213814","author":"O Kontogiannis","year":"2022","unstructured":"Kontogiannis O, Selianitis D, Perinelli DR, Bonacucina G, Pippa N, Gazouli M, et al. Non-ionic surfactant effects on innate Pluronic 188 behavior\u202f: interactions , and physicochemical and biocompatibility studies. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms232213814.","journal-title":"Int J Mol Sci"},{"key":"3401_CR44","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s11051-012-0757-0","volume":"14","author":"M Kakran","year":"2012","unstructured":"Kakran M, Sahoo NG, Tan IL, et al. Preparation of nanoparticles of poorly water-soluble antioxidant curcumin by antisolvent precipitation methods. J Nanopart Res. 2012;14:757. https:\/\/doi.org\/10.1007\/s11051-012-0757-0.","journal-title":"J Nanopart Res"},{"key":"3401_CR45","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/j.addr.2006.09.017","volume":"58","author":"W Abdelwahed","year":"2006","unstructured":"Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freeze-drying of nanoparticles\u202f: formulation , process and storage considerations \u2606. Adv Drug Deliv Rev. 2006;58:1688\u2013713.","journal-title":"Adv Drug Deliv Rev"},{"key":"3401_CR46","doi-asserted-by":"crossref","unstructured":"Thamer AK, Abood AN. Preparation and In vitro Characterization of Aceclofenac Nanosuspension ( ACNS ) for Enhancement of Percutaneous Absorption using Hydrogel Dosage Form \u062a\u0627\u0642\u0628\u0637 \u064a\u0641 \u0621\u0627\u0648\u062f\u0644\u0627 \u0635\u0627\u0635\u062a\u0645\u0627 \u0647\u062f\u0627\u064a\u0632\u0644 \u0643\u0627\u0646\u064a\u0641\u0648\u0644 \u0643\u064a\u0633\u0627 \u0631\u0627\u0642\u0639\u0644 \u0644 \u064a\u0648\u0646\u0627\u0646\u0644\u0627 \u0642\u0644\u0639\u0645\u0644\u0644 \u064a\u0631\u0628\u062a\u062e\u0645\u0644\u0627 \u0645\u064a\u064a\u0642\u062a\u0644\u0627\u0648 \u0631\u064a\u0636\u062d\u062a\u0644\u0627 \u064a\u0626\u0627\u0648\u062f \u0644\u0643\u0634\u0643 \u0645. 2021;30(2):86\u201398.","DOI":"10.31351\/vol30iss2pp86-98"},{"key":"3401_CR47","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/pharmaceutics8020016","volume":"8","author":"A Tuomela","year":"2016","unstructured":"Tuomela A, Hirvonen J, Peltonen L. Stabilizing Agents for Drug Nanocrystals: Effect on Bioavailability Pharmaceutics. 2016;8:16. https:\/\/doi.org\/10.3390\/pharmaceutics8020016.","journal-title":"Stabilizing Agents for Drug Nanocrystals: Effect on Bioavailability Pharmaceutics"},{"issue":"1\u20132","key":"3401_CR48","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ijpharm.2014.10.025","volume":"477","author":"H Yang","year":"2014","unstructured":"Yang H, Teng F, Wang P, Tian B, Lin X, Hu X, et al. Investigation of a nanosuspension stabilized by Soluplus to improve bioavailability. Int J Pharm. 2014;477(1\u20132):88\u201395.","journal-title":"Int J Pharm"},{"key":"3401_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11120688","author":"D Kuk","year":"2019","unstructured":"Kuk D, Ha E, Ha D, Sim W, Lee S, Yoo J, et al. Development of a resveratrol nanosuspension using the antisolvent precipitation method without solvent removal , based on a quality by design ( QbD ) approach. Pharmaceutics. 2019. https:\/\/doi.org\/10.3390\/pharmaceutics11120688.","journal-title":"Pharmaceutics"},{"key":"3401_CR50","doi-asserted-by":"publisher","DOI":"10.1039\/C6RA28676C","author":"J He","year":"2017","unstructured":"He J, Han Y, Xu G, Yin L, Neubi MN, Zhou J. Preparation and evaluation of celecoxib nanosuspensions for bioavailability enhancement. RSC Adv. 2017. https:\/\/doi.org\/10.1039\/C6RA28676C.","journal-title":"RSC Adv"},{"key":"3401_CR51","doi-asserted-by":"publisher","first-page":"8951","DOI":"10.1021\/la061122t","volume":"10","author":"ME Matteucci","year":"2006","unstructured":"Matteucci ME, Hotze MA, Johnston KP, Iii ROW, April RV, Final I, et al. Drug nanoparticles by antisolvent precipitation: mixing energy versus surfactant stabilization. Langmuir. 2006;10:8951\u20139.","journal-title":"Langmuir."},{"key":"3401_CR52","unstructured":"Communication S, Application B, Aghajani M, Barkhordari E, Mostafavi SH. Nanomedicine and Nanoscience Research Effects of Anti-Solvent Flow Rate in the Microfluidic Preparation of. 03(02):10\u20132."},{"key":"3401_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2022.103528","volume":"74","author":"Emilia Jakubowska","year":"2022","unstructured":"Jakubowska Emilia, Bielejewski Michal, Milanowski Bart, Lulek Janina. Freeze-drying of drug nanosuspension\u2013 study of formulation and processing factors for the optimization and characterization of redispersible cilostazol nanocrystals. Journal of Drug Delivery Science and Technology. 2022;74: 103528. https:\/\/doi.org\/10.1016\/j.jddst.2022.103528.","journal-title":"Journal of Drug Delivery Science and Technology."},{"issue":"1","key":"3401_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph12010015","volume":"12","author":"JF Alopaeus","year":"2019","unstructured":"Alopaeus JF, Hages\u00e6ther E, Tho I. Micellisation mechanism and behaviour of soluplus\u00ae\u2013furosemide micelles: preformulation studies of an oral nanocarrier-based system. Pharmaceuticals. 2019;12(1):1\u201323.","journal-title":"Pharmaceuticals"},{"key":"3401_CR55","unstructured":"Sato T. United States Patent\u202f: 5861366 United States Patent\u202f: 5861366. New York [Internet]. 2020;2(19):1\u201329. Available from: https:\/\/patentimages.storage.googleapis.com\/30\/f4\/62\/e9b75605352fb0\/US10679987.pdf. Accessed\u00a012 Jan 2026"},{"issue":"10","key":"3401_CR56","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1016\/j.xphs.2022.04.004","volume":"111","author":"TW Jarrells","year":"2022","unstructured":"Jarrells TW, Munson EJ. Comparison of differential scanning calorimetry, powder X-ray diffraction, and solid-state nuclear magnetic resonance spectroscopy for measuring crystallinity in amorphous solid dispersions - application to drug-in-polymer solubility. J Pharm Sci. 2022;111(10):2765\u201378. https:\/\/doi.org\/10.1016\/j.xphs.2022.04.004.","journal-title":"J Pharm Sci"},{"issue":"3","key":"3401_CR57","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s10973-017-6286-4","volume":"130","author":"M Herbrink","year":"2017","unstructured":"Herbrink M, Schellens J, Beijnen J, Nuijen B. Thermal study of pazopanib hydrochloride. J Therm Anal Calorim. 2017;130(3):1491\u20139.","journal-title":"J Therm Anal Calorim"},{"key":"3401_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2022.133051","volume":"1263","author":"PV Ramana","year":"2022","unstructured":"Ramana PV, Krishna YR, Mouli KC. Experimental FT-IR and UV\u2013Vis spectroscopic studies and molecular docking analysis of anti-cancer drugs Exemestane and Pazopanib. J Mol Struct. 2022;1263:133051. https:\/\/doi.org\/10.1016\/j.molstruc.2022.133051.","journal-title":"J Mol Struct"},{"issue":"6","key":"3401_CR59","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3109\/10837450.2013.813543","volume":"19","author":"GM El Maghraby","year":"2014","unstructured":"El Maghraby GM, Elsergany RN. Fast disintegrating tablets of nisoldipine for intra-oral administration. Pharm Dev Technol. 2014;19(6):641\u201350.","journal-title":"Pharm Dev Technol"},{"key":"3401_CR60","unstructured":"Lan Y, Ali S. Characterization of Soluplus \u00ae by FTIR and Raman Spectroscopy Characterization of Soluplus \u00ae by FTIR and Raman Spectroscopy. 2010;(July):1\u20135."},{"key":"3401_CR61","doi-asserted-by":"publisher","first-page":"927","DOI":"10.3390\/bioengineering10080927","volume":"10","author":"Y Pirincci Tok","year":"2023","unstructured":"Pirincci Tok Y, Mesut B, G\u00fcng\u00f6r S, Sar\u0131kaya AO, Aldeniz EE, Dude U, \u00d6zsoy Y. Systematic Screening Study for the Selection of Proper Stabilizers to Produce Physically Stable Canaglifl ozin Nanosuspension by Wet Milling Method. Bioengineering. 2023;10:927. https:\/\/doi.org\/10.3390\/bioengineering10080927.","journal-title":"Bioengineering"},{"key":"3401_CR62","doi-asserted-by":"crossref","unstructured":"Elsayed NMY, Abou El Ella DA, Serya RAT, Tolba MF, Shalaby R, Abouzid KAM. Design, synthesis and biological evaluation of indazole\u2013pyrimidine based derivatives as anticancer agents with anti-angiogenic and antiproliferative activities. Medchemcomm [Internet]. 2016;7(5):881\u201399. Available from: https:\/\/pubs.rsc.org\/en\/content\/articlehtml\/2016\/md\/c5md00602c. Accessed\u00a012 Jan 2026","DOI":"10.1039\/C5MD00602C"},{"key":"3401_CR63","doi-asserted-by":"publisher","unstructured":"Sun DD, Lee PI. Evolution of Supersaturation of Amorphous Pharmaceuticals: The Effect of Rate of Supersaturation Generation. Mol Pharm [Internet]. 2013;10(11):4330\u201346. Available from: https:\/\/pubs.acs.org\/doi\/abs\/https:\/\/doi.org\/10.1021\/mp400439q","DOI":"10.1021\/mp400439q"},{"issue":"5","key":"3401_CR64","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1021\/mp100049m","volume":"7","author":"JH Fagerberg","year":"2010","unstructured":"Fagerberg JH, Tsinman O, Sun N, Tsinman K, Avdeef A, Bergstr\u00f6m CAS. Dissolution rate and apparent solubility of poorly soluble drugs in biorelevant dissolution media. Mol Pharm. 2010;7(5):1419\u201330.","journal-title":"Mol Pharm"},{"key":"3401_CR65","doi-asserted-by":"publisher","unstructured":"Sugihara H, Taylor LS. Evaluation of Pazopanib Phase Behavior Following pH-Induced Supersaturation. Mol Pharm [Internet]. 2018;15(4):1690\u20139. Available from: https:\/\/pubs.acs.org\/doi\/abs\/https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00081","DOI":"10.1021\/acs.molpharmaceut.8b00081"},{"key":"3401_CR66","doi-asserted-by":"publisher","unstructured":"Mistry P, Suryanarayanan R. Strength of Drug\u2013Polymer Interactions: Implications for Crystallization in Dispersions. Cryst Growth Des [Internet]. 2016;16(9):5141\u20139. Available from: https:\/\/pubs.acs.org\/doi\/abs\/https:\/\/doi.org\/10.1021\/acs.cgd.6b00714","DOI":"10.1021\/acs.cgd.6b00714"},{"key":"3401_CR67","doi-asserted-by":"publisher","unstructured":"Kothari K, Ragoonanan V, Suryanarayanan R. Influence of molecular mobility on the physical stability of amorphous pharmaceuticals in the supercooled and glassy states. Mol Pharm [Internet]. 2014;11(9):3048\u201355. Available from: https:\/\/pubs.acs.org\/doi\/abs\/https:\/\/doi.org\/10.1021\/mp500229d","DOI":"10.1021\/mp500229d"},{"issue":"1","key":"3401_CR68","first-page":"1","volume":"23","author":"Q Shi","year":"2022","unstructured":"Shi Q, Li F, Yeh S, Moinuddin SM, Xin J, Xu J, et al. Recent Advances in Enhancement of Dissolution and Supersaturation of Poorly Water-Soluble Drug in Amorphous Pharmaceutical Solids: A Review. AAPS PharmSciTech. 2022;23(1):1\u201319.","journal-title":"AAPS PharmSciTech"},{"key":"3401_CR69","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.addr.2016.03.006","volume":"101","author":"LS Taylor","year":"2016","unstructured":"Taylor LS, Zhang GGZ. Physical chemistry of supersaturated solutions and implications for oral absorption. Adv Drug Deliv Rev. 2016;101:122\u201342. https:\/\/doi.org\/10.1016\/j.addr.2016.03.006.","journal-title":"Adv Drug Deliv Rev"},{"key":"3401_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119292","volume":"581","author":"GCRM Schver","year":"2020","unstructured":"Schver GCRM, Nadvorny D, Lee PI. Evolution of supersaturation from amorphous solid dispersions in water-insoluble polymer carriers: effects of swelling capacity and interplay between partition and diffusion. Int J Pharm. 2020;581:119292. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119292.","journal-title":"Int J Pharm"},{"key":"3401_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124886","volume":"667","author":"M Fujita","year":"2024","unstructured":"Fujita M, Tsuchida T, Kataoka H, Tsunoda C, Moritake K, Goto S. Spring and parachute approach for piroxicam dissolution; its phenomenological model on the thermodynamics of irreversible processes. Int J Pharm. 2024;667:124886. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.124886.","journal-title":"Int J Pharm"},{"issue":"3","key":"3401_CR72","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1007\/s11095-015-1829-5","volume":"33","author":"J Khan","year":"2016","unstructured":"Khan J, Rades T, Boyd B. The precipitation behavior of poorly water-soluble drugs with an emphasis on the digestion of lipid based formulations. Pharm Res. 2016;33(3):548\u201362.","journal-title":"Pharm Res"},{"issue":"SUPPL. 2","key":"3401_CR73","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0928-0987(00)00181-0","volume":"11","author":"JB Dressman","year":"2000","unstructured":"Dressman JB, Reppas C. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci. 2000;11(SUPPL. 2):73\u201380.","journal-title":"Eur J Pharm Sci"},{"issue":"1\u20132","key":"3401_CR74","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/0378-5173(95)00033-F","volume":"122","author":"M Mosharraf","year":"1995","unstructured":"Mosharraf M, Nystr\u00f6m C. The effect of particle size and shape on the surface specific dissolution rate of microsized practically insoluble drugs. Int J Pharm. 1995;122(1\u20132):35\u201347.","journal-title":"Int J Pharm"},{"issue":"5","key":"3401_CR75","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1080\/05704928.2024.2438747","volume":"60","author":"AA Bunaciu","year":"2025","unstructured":"Bunaciu AA, Hoang VD, Aboul-Enein HY. Fourier transform infrared spectroscopy used in drug excipients compatibility studies. Appl Spectrosc Rev. 2025;60(5):385\u2013403. https:\/\/doi.org\/10.1080\/05704928.2024.2438747.","journal-title":"Appl Spectrosc Rev"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03401-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03401-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03401-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:49:43Z","timestamp":1780390183000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-026-03401-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":75,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["3401"],"URL":"https:\/\/doi.org\/10.1208\/s12249-026-03401-x","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All aspects of animal handling, care, and experi mentation adhere to the ARRIVE guidelines and comply with the UK Animals (Scientific Procedures) Act, 1986, along with associated guidelines and the EU Directive 2010\/63\/EU for animal experiments. The experimental protocol for the pharmacokinetic study was reviewed and approved by the Institutional Animal Ethics Committee of NIPER, S.A.S. Nagar, India.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The authors declare that there are no financial interests, commercial affiliations, or personal relationships that could be construed as potential competing interests with respect to the work reported in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interest"}}],"article-number":"144"}}